Signals, Powered By EquityPandit
The US Food and Drug Administration has provided its final approval to the Aurobindo Pharma Ltd for manufacturing Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets, 600/30 mg and 1200/60mg (OTC) and the drug will be launched during the next quarter.
It has said that “Aurobindo’s Guaifensin and Dextromethorphan Hydrobromide extended-release tablets are the AB rated generic equivalent of Reckitt Benckiser’s Mucinex DM tablets. The product will be launched in Q1 FY18 (in US).”
